SITE010-0238

SITE010 (ESP) › SITE010-0238

SITE010-0238

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2026-06-08

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 3 Aspartate aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-02-27 (study day 72); relationship: not assessed

severe assessed

Data queries

0

No data queries. Open queries would appear here for this patient.